FDA Grants Fast Track Designation to Eli Lilly Diabetes Drug That Might Help People with Obstructive Sleep Apnea Lose Weight
The US Food and Drug Administration (FDA) has granted its Fast Track design for the investigation of tirzepatide for the treatment of adults with obesity or who are overweight with weight-related comorbidities (including obstructive sleep apnea) to facilitate weight loss. Tirzepatide was FDA approved in May 2022 as an adjunct to diet and exercise to … Read more
